Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A2 | O15244 | 5/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.35 |
| ▸ | ALKBH1 | Q13686 | 3/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMO | O15229 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24969606 | 0.92 | SLC22A2 (0.41) | SLC22A2CYP3A4TMEM97ABCG2S1PR5 | |
| SCHEMBL19921592 | 0.91 | SLC22A2 (0.48) | SLC22A2CYP3A4TMEM97ABCG2ALKBH1 | |
| SCHEMBL14866503 | 0.91 | SLC22A2 (0.48) | SLC22A2CYP3A4TMEM97ABCG2ALKBH1 | |
| SCHEMBL2161654 | 0.86 | GRM2 (0.36) | SLC22A2S1PR5GRM2GLRA1LMNA | |
| SCHEMBL21780072 | 0.86 | GRM2 (0.36) | SLC22A2S1PR5GRM2GLRA1LMNA | |
| SCHEMBL82203 | 0.85 | SLC22A2 (0.49) | SLC22A2CYP3A4TMEM97ABCG2LMNA | |
| SCHEMBL12319716 | 0.84 | SLC22A2 (0.49) | SLC22A2CYP3A4TMEM97ABCG2LMNA | |
| SCHEMBL26287678 | 0.84 | SLC22A2 (0.49) | SLC22A2CYP3A4TMEM97ABCG2LMNA | |
| SCHEMBL18755768 | 0.84 | SLC22A2 (0.49) | SLC22A2CYP3A4TMEM97ABCG2LMNA | |
| SCHEMBL19755592 | 0.83 | SLC22A2 (0.43) | SLC22A2CYP3A4TMEM97ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230020329-A1 | Annelated 9-hydroxy-1,8-dioxo-1,3,4,8-tetrahydro-2H-pyrido[1,2-a]pyrazine-7-carboxamides as HIV integrase inhibitors, methods of preparation and application thereof | Ivachtchenko Alexandrovna Alena (US) | 2023-01-19 | — | — | US | disclosed |
| EP-3978503-A1 | ANNELATED 9-HYDROXY-1,8-DIOXO-1,3,4,8-TETRAHYDRO-2H-PYRIDO[1,2-a]PYRAZINE-7-CARBOXAMIDES AS HIV INTEGRASE INHIBITORS | Ivachtchenko, Alena Alexandrovna (US) | 2022-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230020329-A1 | Annelated 9-hydroxy-1,8-dioxo-1,3,4,8-tetrahydro-2H-pyrido[1,2-a]pyrazine-7-carboxamides as HIV integrase inhibitors, methods of preparation and application thereof | CDK9, DPYD, INTS9 | SLC22A2 3786/4885CYP3A4 31/4885TMEM97 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.